JP5129563B2 - 視神経症に対する感受性を診断または予測するための方法 - Google Patents

視神経症に対する感受性を診断または予測するための方法 Download PDF

Info

Publication number
JP5129563B2
JP5129563B2 JP2007503564A JP2007503564A JP5129563B2 JP 5129563 B2 JP5129563 B2 JP 5129563B2 JP 2007503564 A JP2007503564 A JP 2007503564A JP 2007503564 A JP2007503564 A JP 2007503564A JP 5129563 B2 JP5129563 B2 JP 5129563B2
Authority
JP
Japan
Prior art keywords
polymorphism
gene
patients
endothelin
genotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007503564A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007529218A (ja
JP2007529218A5 (https=
Inventor
行彦 真島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rusk Intellectual Reserve AG
Original Assignee
Rusk Intellectual Reserve AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rusk Intellectual Reserve AG filed Critical Rusk Intellectual Reserve AG
Publication of JP2007529218A publication Critical patent/JP2007529218A/ja
Publication of JP2007529218A5 publication Critical patent/JP2007529218A5/ja
Application granted granted Critical
Publication of JP5129563B2 publication Critical patent/JP5129563B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007503564A 2004-03-18 2005-03-18 視神経症に対する感受性を診断または予測するための方法 Expired - Fee Related JP5129563B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US55398604P 2004-03-18 2004-03-18
US60/553,986 2004-03-18
US60470404P 2004-08-27 2004-08-27
US60/604,704 2004-08-27
US60735904P 2004-09-07 2004-09-07
US60/607,359 2004-09-07
PCT/JP2005/005601 WO2005090602A2 (en) 2004-03-18 2005-03-18 Method for diagnosing or predicting susceptibility to optic nueropathy

Publications (3)

Publication Number Publication Date
JP2007529218A JP2007529218A (ja) 2007-10-25
JP2007529218A5 JP2007529218A5 (https=) 2008-05-08
JP5129563B2 true JP5129563B2 (ja) 2013-01-30

Family

ID=34979405

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007503564A Expired - Fee Related JP5129563B2 (ja) 2004-03-18 2005-03-18 視神経症に対する感受性を診断または予測するための方法

Country Status (3)

Country Link
US (1) US8182990B2 (https=)
JP (1) JP5129563B2 (https=)
WO (1) WO2005090602A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2619303T3 (es) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
JP5308328B2 (ja) 2006-04-04 2013-10-09 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
KR20100016525A (ko) * 2007-04-17 2010-02-12 산뗀세이야구가부시기가이샤 녹내장 진행 리스크의 판정 방법
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
WO2010044459A1 (ja) * 2008-10-16 2010-04-22 独立行政法人国立病院機構 緑内障のリスクの予測方法
JP4515524B2 (ja) * 2008-11-27 2010-08-04 株式会社メニコン 正常眼圧緑内障疾患感受性遺伝子及びその利用
US20100197537A1 (en) * 2009-02-02 2010-08-05 R.T. Vanderbilt Company, Inc. Ashless lubricant composition
US9315760B2 (en) 2009-02-02 2016-04-19 Vanderbilt Chemicals, Llc Ashless lubricant composition
EA201101576A1 (ru) * 2009-04-28 2012-04-30 Эдисон Фармасьютикалз, Инк. Лекарственная форма токотриенол хинонов для лечения офтальмических (глазных) заболеваний
CA2777479C (en) 2009-04-28 2017-10-17 Ptc Therapeutics, Inc. Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
GB201006197D0 (en) * 2010-04-14 2010-06-02 Univ Edinburgh Genetic markers for PDB
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
RU2597784C2 (ru) * 2014-11-19 2016-09-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ прогнозирования риска развития первичной открытоугольной глаукомы у индивидуумов в зависимости от наличия/отсутствия сопутствующей патологии глаз
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP7072803B2 (ja) * 2016-06-30 2022-05-23 京都府公立大学法人 広義原発開放隅角緑内障の発症リスクの判定方法
IT201700079495A1 (it) * 2017-07-14 2019-01-14 Optikon 2000 Spa Sistema e metodo di controllo della pressione di infusione oculare per interventi di chirurgia oftalmica

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT943014E (pt) * 1996-12-05 2007-03-30 Alcon Mfg Ltd Métodos para diagnóstico do glaucoma e descoberta de farmacos antiglaucoma
US6475724B1 (en) * 1997-01-28 2002-11-05 The Regents Of The University Of California Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
AU2001294559A1 (en) * 2000-09-11 2002-03-26 Dzgenes, L.L.C. Endothelin-1 promoter polymorphism
WO2002024747A2 (en) * 2000-09-19 2002-03-28 Epidauros Biotechnologie Ag Polymorphisms in human genes of cardiovascular regulators and their use in diagnostic and therapeutic applications

Also Published As

Publication number Publication date
JP2007529218A (ja) 2007-10-25
US8182990B2 (en) 2012-05-22
WO2005090602A3 (en) 2006-04-13
WO2005090602A2 (en) 2005-09-29
US20080221050A1 (en) 2008-09-11

Similar Documents

Publication Publication Date Title
JP5129563B2 (ja) 視神経症に対する感受性を診断または予測するための方法
Aung et al. A major marker for normal tension glaucoma: association with polymorphisms in the OPA1 gene
JP5535914B2 (ja) Ｓｎｐ遺伝子型に基づく抗精神病薬治療
US20120107315A1 (en) Predicting progression to advanced age-related macular degeneration using a polygenic score
CA2851510A1 (en) Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
WO2010075519A2 (en) Allelic variants associated with advanced age-related macular degeneration
Gorin Identification of mutations in UBIAD1 following exclusion of coding mutations in the chromosome 1p36 locus for Schnyder crystalline corneal dystrophy
US20160102353A1 (en) Polymorphisms Associated With Age-Related Macular Degeneration and Methods for Evaluating Patient Risk
US20070037183A1 (en) Diagnostic and therapeutic target for macular degeneration
US20090075827A1 (en) Diagnostic methods and agents
Niazi et al. Association of 2 Lysyl oxidase gene single nucleotide polymorphisms with keratoconus: a nationwide registration study
Wolf et al. Lysyl oxidase-like 1 gene polymorphisms in German patients with normal tension glaucoma, pigmentary glaucoma and exfoliation glaucoma
US7906283B2 (en) Methods to identify patients at risk of developing adverse events during treatment with antidepressant medication
US8088587B2 (en) Genetic variants increase the risk of age-related macular degeneration
Cui et al. Genotypes of SNPs of key genes regulate susceptibility and drug sensitivity to neovascular AMD in the human population
US20110104154A1 (en) Single nucleotide polymorphisms and genes associated with age-related macular degeneration
US20160312284A1 (en) Select single nucleotide polymorphisms predictive of response to glatiramer acetate
JP5578536B2 (ja) 高血圧の遺伝的リスク検出法
US8236497B2 (en) Methods of diagnosing cardiovascular disease
US20180023141A1 (en) Method for determining a therapeutic approach for the treatment of age-related macular degeneration (amd)
JP4590526B2 (ja) 双極性障害検査方法及び検査薬
US20070117095A1 (en) Diagnostic method for neonatal or infantile epilepsy syndromes
EP3045541A1 (en) Test method for evaluating the risk of anti-thyroid drug-induced agranulocytosis, and evaluation kit
JP2004141112A (ja) ２型糖尿病患者における動脈硬化に対する易罹患性の判定方法
JP2021145608A (ja) 治療抵抗性高血圧の検査方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080317

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080317

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080827

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110301

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110518

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110525

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121023

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121102

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151109

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees